Akoya

Akoya Biosciences Announces Public Offering of Common Stock

Retrieved on: 
Mercredi, juin 7, 2023
Morgan Stanley, Attention, Varick Street, Telephone, Akoya, Sale, Prospectus, Offering, Form, 2nd Floor, Life insurance, Security (finance)

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”).

Key Points: 
  • MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”).
  • In addition, Akoya expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.
  • Akoya intends to use the net proceeds from the Offering for working capital and general corporate purposes.
  • A final prospectus supplement and the accompanying prospectus relating to the Offering will be filed by Akoya with the SEC.

Akoya Partners With Axway to Help Financial Institutions Tap Into the Power of Open APIs

Retrieved on: 
Jeudi, juin 1, 2023
Fintech, Professional Services, Finance, CFPB, Partnership, Financial services, FDX, API, Akoya, Friction, Consumer Financial Protection Bureau, Consumer, Amplification, Mobile phone, Cryptocurrency

Akoya is proud to announce its partnership with Axway to transform the way customer information is shared with third-party applications.

Key Points: 
  • Akoya is proud to announce its partnership with Axway to transform the way customer information is shared with third-party applications.
  • Both companies have standardized their APIs to the Financial Data Exchange (FDX) standard, which allows for customer data sharing in a secure and transparent way.
  • As North America prepares for upcoming regulation, Akoya and Axway are poised to help financial institutions tap into the power of the open finance ecosystem and unlock new business models.
  • Learn more about how Axway is helping financial institutions tap into the API-fueled financial ecosystem, here .

Jack Henry Continues Phase Out of Screen Scraping on the Banno Digital Banking Platform

Retrieved on: 
Mardi, mai 23, 2023
CFPB, Plague, JKHY, John Henry, API, Akoya, Intuit, Fraud, Cryptocurrency, Online shopping

MONETT, Mo., May 23, 2023 /PRNewswire/ -- Jack Henry™ (Nasdaq: JKHY) announced it continues to replace inbound screen scraping on its Banno Digital Banking Platform with API connections to all five major data exchange platforms, Finicity, Akoya, Plaid, Envestnet | Yodlee, and Intuit, giving accountholders more control of their financial data and protecting financial institutions from a wide range of fraud and security risks that arise from passwords shared with third parties. Screen scraping, while a common practice throughout the industry, presents multiple challenges in both security and customer experience; Jack Henry is on track to eliminate all inbound screen scraping on its Banno Digital Banking Platform by the end of summer this year.

Key Points: 
  • Screen scraping, while a common practice throughout the industry, presents multiple challenges in both security and customer experience; Jack Henry is on track to eliminate all inbound screen scraping on its Banno Digital Banking Platform by the end of summer this year.
  • Replacing inbound screen scraping for the more than 700 banks and credit unions on Jack Henry's Banno Digital Banking Platform inaugurates a new and more secure era of financial data exchange.
  • "Screen scraping is an outdated, broken process," said Ben Metz, chief digital and technology officer at Jack Henry.
  • Jack Henry is working with the banks and credit unions on its Banno Digital Banking Platform to make a smooth transition from screen scraping to secure, API-based financial data exchange.

DISCOVERY LIFE SCIENCES JOINS AKOYA BIOSCIENCES' GLOBAL SERVICE PROVIDER NETWORK TO ACCELERATE IMMUNO-ONCOLOGY RESEARCH

Retrieved on: 
Jeudi, mai 18, 2023
Artificial intelligence, Discovery, Tumor microenvironment, Discovery Life, Machine learning, HT, TME, Microscope, Medical imaging, Biological specimen, Akoya

HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers.

Key Points: 
  • HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers.
  • The qualification process evaluated Discovery's proficiency in staining, imaging, and analysis―allowing the company to deliver comprehensive spatial imaging services to researchers across discovery, translational, and clinical research.
  • As a qualified provider, Discovery has received additional tools for quantitative QC of future panels and operator and autostainer consistency.
  • "Being qualified as a global service provider of Akoya is a significant milestone for Discovery," said Christiaan Neeleman, head of Global Tissue Biomarker Services at Discovery.

DISCOVERY LIFE SCIENCES JOINS AKOYA BIOSCIENCES' GLOBAL SERVICE PROVIDER NETWORK TO ACCELERATE IMMUNO-ONCOLOGY RESEARCH

Retrieved on: 
Jeudi, mai 18, 2023
Artificial intelligence, Discovery, Tumor microenvironment, Discovery Life, Machine learning, HT, TME, Microscope, Medical imaging, Biological specimen, Akoya

HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers.

Key Points: 
  • HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences' global service providers.
  • The qualification process evaluated Discovery's proficiency in staining, imaging, and analysis―allowing the company to deliver comprehensive spatial imaging services to researchers across discovery, translational, and clinical research.
  • As a qualified provider, Discovery has received additional tools for quantitative QC of future panels and operator and autostainer consistency.
  • "Being qualified as a global service provider of Akoya is a significant milestone for Discovery," said Christiaan Neeleman, head of Global Tissue Biomarker Services at Discovery.

Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance

Retrieved on: 
Lundi, mai 8, 2023
Cloud, AACR, General counsel, Workflow, HT, Akoya, Research, Instrument, Data analysis, Traction, Publication, Investment, Growth, Total, Software, Pharmaceutical industry, Video game, Film industry, Management

MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2023.

Key Points: 
  • Q1 2023 revenue $21.4 million, 27% y/y growth
    MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2023.
  • Product revenue (which includes instruments, reagents, and software) was $15.5 million in the first quarter of 2023, compared to $13.3 million in the prior year period; an increase of 16.5%.
  • The Company, based on its current plans and initiatives, continues to expect full year 2023 revenue guidance range of $95-98 million.
  • Akoya will host a conference call today, May 8, 2023, at 5:00 p.m. Eastern Time to discuss its first quarter 2023 financial results.

Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument

Retrieved on: 
Jeudi, avril 27, 2023
Histology, Akoya, Ecosystem, Software, Medical imaging

MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it’s 1,000th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry.

Key Points: 
  • MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it’s 1,000th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry.
  • Akoya platforms have gained widespread adoption in discovery and translational research laboratories around the world, setting the stage for clinical use.
  • Akoya’s industry leading instrument portfolio includes the PhenoCycler®, PhenoImager® Fusion and the PhenoImager HT.
  • “The shipment of our 1,000th instrument is a testament to our unique ability to deliver end-to-end spatial solutions that enable the identification and validation of spatial biomarkers with the potential for use in the clinical setting to improve patient outcomes,” said Brian McKelligon, CEO of Akoya Biosciences.

Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data

Retrieved on: 
Mercredi, avril 12, 2023
Cloud, Data management, Software as a service, Partnership, AACR, American Association for Cancer Research, Data analysis, Knowledge, Ecosystem, Medical imaging, Akoya

MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya’s PhenoCycler-Fusion system.

Key Points: 
  • MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced they are partnering with Enable Medicine to introduce a cloud platform capable of significantly accelerating the analysis of high plex spatial image datasets generated by Akoya’s PhenoCycler-Fusion system.
  • Demos of the cloud platform will be available at the Akoya booth (#1713) at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.
  • Available as software-as-a-solution (SaaS) package for PhenoCycler-Fusion users, the Enable Cloud Platform is an end-to-end spatial cloud solution for data management, image analysis, and mapping predictive spatial signatures.
  • This compressed and standardized data format simplifies and catalyzes partnerships with cutting-edge solutions like the Enable Cloud Platform.”
    The Enable Cloud Platform has been optimized on more than 20,000 samples run on the PhenoCycler platform and is an ideal cloud solution for large spatial imaging datasets.

Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow

Retrieved on: 
Mercredi, avril 12, 2023
AACR, Workflow, Neoplasm, Heart, International Workshop on Lung Health, American Association for Cancer Research, Research, Biomarker, RNA, Doctor of Philosophy, ILH, International Max Planck Research School for Heart and Lung Research, Ecosystem, Tumor microenvironment, Pharmaceutical industry, Akoya

PhenoCode Discovery Panels are designed to advance cancer research by enabling thorough interrogation of tumors and the surrounding tumor microenvironment.

Key Points: 
  • PhenoCode Discovery Panels are designed to advance cancer research by enabling thorough interrogation of tumors and the surrounding tumor microenvironment.
  • “The PhenoCode Discovery Panels further streamline and simplify the workflow on the PhenoCycler-Fusion System, offering new avenues of exploration for existing customers and paving the way for researchers who want to leverage this powerful technology for the first time,” said Brian McKelligon, CEO of Akoya.
  • “These panels are an important part of the spatial biology ecosystem which Akoya has established and continues to expand.
  • We expect to launch additional PhenoCode Discovery Panels for protein biomarkers throughout 2023 and 2024, and introduce panels for RNA in the second half of this year.”
    The PhenoCode Discovery Panels will be highlighted at booth #1713 at AACR.

Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023

Retrieved on: 
Jeudi, avril 6, 2023
Cryptocurrency, Online shopping, Akoya

MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023.

Key Points: 
  • MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023.
  • Company management will host a conference call to discuss financial results at 5:00 p.m.
  • Investors interested in listening to the conference call are required to register online .
  • A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/ .